Printer Friendly

BIOMUNE SYSTEMS, INC. ANNOUNCES PRECLINICAL DRUG FOR E. COLI

 SALT LAKE CITY, Feb. 19 /PRNewswire/ -- Biomune Systems, Inc., a biogenetic company specializing in drugs that build the immune system, announced today a preclinical drug that has proven to be effective in preventing and treating E. coli bacterial diseases in animals. David Derrick, president of the company, stated that the same class of bacterial diseases is what caused the tragic E. coli epidemic in the Northwest in which hundreds have been stricken. The cases, most of them linked to undercooked hamburgers at Jack in the Box restaurants, could be the precursor of much larger epidemics considering the amounts of fast food now consumed worldwide.
 According to Derrick, Biomune's USDA approved drug has successfully treated tens of thousands of animals for E. coli diseases worldwide over the past seven years.
 Biomune's drugs are covered by patents for a process to produce large Ig proteins (immunoglobulins) on a production basis. These Ig proteins which are derived from a natural organic source, are the soldiers that fight off disease in humans. They could neutralize a wide range of disease viruses and bacteria such as ulcers, various gastroenterological diseases, travelers' diarrhea, AIDS related ailments, and even help immune impaired cancer patients.
 -0- 2/19/93
 /CONTACT: David Derrick, president of Biomune Systems, Inc., 801-364-5850/


CO: Biomune Systems, Inc. ST: Utah IN: MTC SU:

LD -- NY071 -- 8576 02/19/93 17:20 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 19, 1993
Words:228
Previous Article:CONNECTICUT $225 MILLION TRANSPORTATION REFUNDING BONDS RATED 'AA-' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:MID-BAY BRIDGE AUTHORITY (FL) REFUNDING BONDS RATED BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
BIOMUNE SYSTEMS, INC. ANNOUNCES PRECLINICAL DRUG FOR PREVENTING AND TREATING CRYPTOSPORIDIOSIS IN ANIMALS
MicroCarb Receives U.S. Patent For E.Coli 0157:H7 Toxin Detection Test
SYNSORB Biotech Inc. Forms Strategic Alliance With Japan's Largest Pharmaceutical Company
Affymetrix Introduces GeneChip(R) E. coli Genome Probe Array.
Affymetrix introduces Genechip E. coli genome probe array.
Biomune Systems, Inc. Announces Donlar Corporation Will Transfer Certain Assets in Exchange for Biomune Common Stock.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters